Corcept Therapeutics Incorporated (CORT)vsNovartis AG ADR (NVS)
CORT
Corcept Therapeutics Incorporated
$112.79
-1.85%
HEALTHCARE · Cap: $12.32B
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6724% more annual revenue ($56.69B vs $830.81M). NVS leads profitability with a 22.5% profit margin vs 6.6%. CORT appears more attractively valued with a PEG of 0.81. CORT earns a higher WallStSmart Score of 60/100 (C+).
CORT
Buy60
out of 100
Grade: C+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CORT.
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 31.7% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Earnings expanding 24.1% YoY
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
Trading at 17.2x book value
ROE of 7.8% — below average capital efficiency
6.6% margin — thin
Weak financial health signals
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : CORT
The strongest argument for CORT centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 31.7% demonstrates continued momentum. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : CORT
The primary concerns for CORT are Price/Book, Return on Equity, Profit Margin. A P/E of 253.3x leaves little room for execution misses.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
CORT profiles as a hypergrowth stock while NVS is a value play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.49 — expect wider price swings.
CORT is growing revenue faster at 31.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
CORT scores higher overall (60/100 vs 51/100) and 31.7% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Corcept Therapeutics Incorporated
HEALTHCARE · BIOTECHNOLOGY · USA
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?